Home  /  Resource Library  /  One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

ASH 2020: Follow up of a study examining CAR T therapy brexucabtagene autoleucel for treatment of relapsed mantle cell lymphoma.